Compare GOOS & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GOOS | OMER |
|---|---|---|
| Founded | 1957 | 1994 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 894.8M |
| IPO Year | 2017 | 2009 |
| Metric | GOOS | OMER |
|---|---|---|
| Price | $11.93 | $11.93 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $12.60 | ★ $32.50 |
| AVG Volume (30 Days) | 1.0M | ★ 1.4M |
| Earning Date | 02-05-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $1,067,658,612.00 | N/A |
| Revenue This Year | $8.87 | N/A |
| Revenue Next Year | $5.93 | N/A |
| P/E Ratio | $75.41 | ★ N/A |
| Revenue Growth | ★ 10.42 | N/A |
| 52 Week Low | $6.73 | $2.95 |
| 52 Week High | $15.43 | $17.65 |
| Indicator | GOOS | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 45.14 | 50.35 |
| Support Level | $11.67 | $11.00 |
| Resistance Level | $12.42 | $11.46 |
| Average True Range (ATR) | 0.62 | 0.60 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 53.58 | 60.45 |
Canada Goose Holdings Inc is a Canada-based company that designs, manufactures, distributes, and retails premium outerwear for men, women, and children. It operates business through three segments namely, Wholesale and Direct to Consumer (DTC), Other. The DTC segment, which is the key revenue driver, comprises sales through country-specific e-commerce platforms and its company-owned retail stores located in luxury shopping locations. The Wholesale segment comprises sales made to a mix of retailers and international distributors, who are partners that have exclusive rights to an entire market, and travel retail locations. Geographically, it has a presence in Canada, the United States, North America, Greater China, Asia, and Europe, the Middle East, and Africa.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.